<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://eln.excellgen.com/index.php?action=history&amp;feed=atom&amp;title=Construction_of_the_human_antibody_gene_libraries</id>
	<title>Construction of the human antibody gene libraries - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://eln.excellgen.com/index.php?action=history&amp;feed=atom&amp;title=Construction_of_the_human_antibody_gene_libraries"/>
	<link rel="alternate" type="text/html" href="https://eln.excellgen.com/index.php?title=Construction_of_the_human_antibody_gene_libraries&amp;action=history"/>
	<updated>2026-10-18T04:26:30Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.0</generator>
	<entry>
		<id>https://eln.excellgen.com/index.php?title=Construction_of_the_human_antibody_gene_libraries&amp;diff=17850&amp;oldid=prev</id>
		<title>Paul.xu at 22:03, 2 May 2018</title>
		<link rel="alternate" type="text/html" href="https://eln.excellgen.com/index.php?title=Construction_of_the_human_antibody_gene_libraries&amp;diff=17850&amp;oldid=prev"/>
		<updated>2018-05-02T22:03:28Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Lymphocytes were isolated from 44 donors with various ethnical&amp;lt;br/&amp;gt;backgrounds using the Lymphoprep Kit (Progen, Heidelberg)&amp;lt;br/&amp;gt;according to the manufacturers instructions. Total RNA was isolated&amp;lt;br/&amp;gt;using Trizol (Invitrogen, Karlsruhe) and mRNA (from all&amp;lt;br/&amp;gt;samples) was isolated using the QuickPrep micro mRNA Purification&amp;lt;br/&amp;gt;Kit (GE Healthcare, München) leading to 81 RNA preparations.&amp;lt;br/&amp;gt;Then cDNA was synthesised separately from each RNA sample&amp;lt;br/&amp;gt;using Superscript II (Invitrogen), random hexamer oligonucleotide&amp;lt;br/&amp;gt;primers and 50–250 ng mRNA or 2–20ug total RNA, respectively.&amp;lt;br/&amp;gt;To amplify the antibody gene fragments (kappa, lambda, VH) 27&amp;lt;br/&amp;gt;individual first PCRs of each cDNA sample were performed separately&amp;lt;br/&amp;gt;for each cDNA preparation in a volume of 50uL using Red Taq&amp;lt;br/&amp;gt;(Sigma, Hamburg) and 0.4uMof each primer (Table 1) for 30 cycles&amp;lt;br/&amp;gt;(1 min 94 ◦C, 1min 55 ◦C, 2min 72 ◦C) followed by a 10 min final&amp;lt;br/&amp;gt;synthesis step. The PCR products were purified by agarose gel electrophoresis&amp;lt;br/&amp;gt;using the Nucleospin Extract 2 Kit (Macherey-Nagel,&amp;lt;br/&amp;gt;Düren). The VH, kappa or lambda PCR products were pooled separately.&amp;lt;br/&amp;gt;To add restriction sites for cloning, 100 ng of the purified and&amp;lt;br/&amp;gt;pooled VH, kappa or lambda PCR products of the first PCR for each&amp;lt;br/&amp;gt;of the 27 s PCR reactions were used in a volume of 100uL using&amp;lt;br/&amp;gt;Red Taq and 0.2uM of each primer (Table 1) for 20 cycles (1 min&amp;lt;br/&amp;gt;94 ◦C, 1min 57 ◦C, 2min 72 ◦C) followed by a 10min final synthesis&amp;lt;br/&amp;gt;step at 72 ◦C. The PCR products were purified by agarose gel electrophoresis&amp;lt;br/&amp;gt;using the Nucleospin Extract 2 Kit and VH, kappa or&amp;lt;br/&amp;gt;lambda were pooled separately. In total 2187 first PCR and 2187 s&amp;lt;br/&amp;gt;PCR reactions were performed.&amp;lt;br/&amp;gt;For VL cloning 5ug vector pHAL14 and 2ug kappa or lambda&amp;lt;br/&amp;gt;PCR products were digested in a volume of 100uL using 30U&amp;lt;br/&amp;gt;MluI and NotI (NEB, Frankfurt) at 37 ◦C for 2 h. This step was performed&amp;lt;br/&amp;gt;multiple times to produce enough material for up to 20&amp;lt;br/&amp;gt;transformations. For quality control each digestion was performed&amp;lt;br/&amp;gt;separately with each enzyme in parallel. The digestions were inactivated&amp;lt;br/&amp;gt;at 65 ◦C for 10 min, followed by adding 0.5U calf intestine&amp;lt;br/&amp;gt;phosphatase (CIP) (MBI Fermentas, St. Leon-Rot) and incubation&amp;lt;br/&amp;gt;at 37 ◦C for 30 min, this step was repeated once. The vector and&amp;lt;br/&amp;gt;the PCR products were purified using the Nucleospin Extract 2 Kit,&amp;lt;br/&amp;gt;removing short stuffer fragments containing multiple stop codons&amp;lt;br/&amp;gt;between MluI and NotI in pHAL14. Each ligation was performed&amp;lt;br/&amp;gt;with 1ug digested vector and 270 ng PCR product using 3U T4&amp;lt;br/&amp;gt;ligase (Promega, Mannheim) in a volume of 100uL overnight at&amp;lt;br/&amp;gt;16 ◦C. The ligations were inactivated at 65 ◦C for 10 min and precipitated&amp;lt;br/&amp;gt;with 10uL 3Msodium acetate pH 5.2 and 250uL ethanol for&amp;lt;br/&amp;gt;2min at RT, followed by 5min centrifugation at 16,000×g and 4 ◦C.&amp;lt;br/&amp;gt;The pellet was washed two times with 500uL 70% (v/v) ethanol.&amp;lt;br/&amp;gt;The dried pellet was resuspended in 35uL dH2O and mixed on ice&amp;lt;br/&amp;gt;with 25uL electrocompetent XL1-Blue MRF&amp;#039;. The electroporation&amp;lt;br/&amp;gt;was performed with 0.1cm prechilled cuvettes using aMicroPulser&amp;lt;br/&amp;gt;electroporator (BIO-RAD, München) at 1.7 kV. Immediately, 1mL&amp;lt;br/&amp;gt;prewarmed 37 ◦C SOC medium pH 7.0 (2% (w/v) tryptone, 0.5%&amp;lt;br/&amp;gt;(w/v) yeast extract, 0.05% (w/v) NaCl, 20mM Mg solution, 20mM&amp;lt;br/&amp;gt;glucose) was added and incubated for 1 h at 600rpm and 37 ◦C. The&amp;lt;br/&amp;gt;transformation was plated out on 25cm square Petri dishes with&amp;lt;br/&amp;gt;2xYT-GAT agar (1.6% (w/v) tryptone, 1% (w/v) yeast extract, 0.5%&amp;lt;br/&amp;gt;(w/v) NaCl, 100mMglucose, 100ug/mL ampicillin, 20ug/mL tetracycline,&amp;lt;br/&amp;gt;1.5% (w/v) agar–agar) and incubated overnight at 37 ◦C.&amp;lt;br/&amp;gt;In parallel 10−6 dilutions were plated out to determine the transformation&amp;lt;br/&amp;gt;rate. These plates were used also for quality control&amp;lt;br/&amp;gt;by colony PCR using the oligonucleotide primers MHLacZ-Pro f&amp;lt;br/&amp;gt;and MHgIII r (Table 1) to verify the insert size. The colonies were&amp;lt;br/&amp;gt;scraped from the 25cm plates using 40mL 2xYT medium (1.6%&amp;lt;br/&amp;gt;(w/v) tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl) and 5mL&amp;lt;br/&amp;gt;were directly used for midi plasmid preparation using the Nucleobond&amp;lt;br/&amp;gt;Plasmid Midi Kit (Macherey-Nagel).&lt;br /&gt;
&lt;br /&gt;
Lymphocytes were isolated from 54 donors with various&amp;lt;br/&amp;gt;ethnical backgrounds using the Lymphoprep Kit&amp;lt;br/&amp;gt;(Progen, Heidelberg) according to the manufacturers&amp;lt;br/&amp;gt;instructions. Total RNA was isolated using Trizol&amp;lt;br/&amp;gt;(Invitrogen, Karlsruhe) and mRNA was isolated using&amp;lt;br/&amp;gt;the Oligotex mRNA Minikit (Qiagen, Hilden). Then&amp;lt;br/&amp;gt;cDNA was synthesized using Superscript III (Invitrogen),&amp;lt;br/&amp;gt;random hexamer oligonucleotide primers and&amp;lt;br/&amp;gt;50–250 ng mRNA.&amp;lt;br/&amp;gt;To amplify the antibody gene fragments (kappa,&amp;lt;br/&amp;gt;lambda, VH) 27 individual first PCRs of each cDNA&amp;lt;br/&amp;gt;sample were performed separately for each cDNA preparation&amp;lt;br/&amp;gt;in a volume of 50 μL using GoTaq (Promega,&amp;lt;br/&amp;gt;Mannheim) and 0.4 μM of each primer [40] for 30 cycles&amp;lt;br/&amp;gt;(1 min 95°C, 1 min 55°C, 2 min 72°C) followed by a&amp;lt;br/&amp;gt;10 min final synthesis step. The PCR products were&amp;lt;br/&amp;gt;purified by agarose gel electrophoresis using the&amp;lt;br/&amp;gt;NucleoSpin Gel and PCR Clean-up Kit (Macherey-&amp;lt;br/&amp;gt;Nagel, Düren). VH, kappa or lambda PCR products were&amp;lt;br/&amp;gt;pooled separately. To add restriction sites for cloning,&amp;lt;br/&amp;gt;100 ng of the purified and pooled VH, kappa or lambda&amp;lt;br/&amp;gt;PCR products of the first PCR for each of the 27 second&amp;lt;br/&amp;gt;PCR reactions were used in a volume of 100 μL using&amp;lt;br/&amp;gt;GoTaq and 0.2 μM of each primer for 20 cycles (1 min&amp;lt;br/&amp;gt;95°C, 1 min 57°C, 2 min 72°C) followed by a 10 min&amp;lt;br/&amp;gt;final synthesis step at 72°C. PCR products were purified&amp;lt;br/&amp;gt;by agarose gel electrophoresis using the NucleoSpin Gel&amp;lt;br/&amp;gt;and PCR Clean-up Kit (Macherey-Nagel, Düren). VH,&amp;lt;br/&amp;gt;kappa or lambda PCR products were pooled separately.&amp;lt;br/&amp;gt;In total 1458 first PCR and 1458 second PCR reactions&amp;lt;br/&amp;gt;were performed.&lt;br /&gt;
&lt;br /&gt;
For VL cloning 5 μg vector pHAL30 and 2 μg kappa or&amp;lt;br/&amp;gt;lambda PCR products were digested in a volume of 100 μL&amp;lt;br/&amp;gt;using 30 U MluI and NotI (NEB, Frankfurt) at 37°C for&amp;lt;br/&amp;gt;3 h. This step was performed multiple times to produce&amp;lt;br/&amp;gt;enough material for up to 50 transformations. For quality&amp;lt;br/&amp;gt;control each digestion was performed separately&amp;lt;br/&amp;gt;with each enzyme in parallel. The digestions were inactivated&amp;lt;br/&amp;gt;at 80°C for 20 min, followed by adding 0.5 U&amp;lt;br/&amp;gt;calf intestine phosphatase (CIP) (MBI Fermentas, St.&amp;lt;br/&amp;gt;Leon-Rot) and incubation at 37°C for 30 min, this step&amp;lt;br/&amp;gt;was repeated once. Vector and PCR products were&amp;lt;br/&amp;gt;purified using the NucleoSpin Gel and PCR Clean-up&amp;lt;br/&amp;gt;Kit, removing short stuffer fragments between MluI&amp;lt;br/&amp;gt;and NotI in pHAL30. Each ligation was performed with&amp;lt;br/&amp;gt;1 μg digested vector and 270 ng PCR product using 3&amp;lt;br/&amp;gt;U T4 ligase (Promega, Mannheim) in a volume of&amp;lt;br/&amp;gt;100 μL overnight at 16°C. Ligations were inactivated at&amp;lt;br/&amp;gt;70°C for 10 min and precipitated with 10 μL 3 M sodium&amp;lt;br/&amp;gt;acetate pH 5.2 and 250 μL ethanol for 2 min at RT,&amp;lt;br/&amp;gt;followed by 5 min centrifugation at 16000 × g and 4°C.&amp;lt;br/&amp;gt;Pellet was washed two times with 500 μL 70% (v/v)&amp;lt;br/&amp;gt;ethanol. The dried pellet was resuspended in 35 μL&amp;lt;br/&amp;gt;dH2O and mixed on ice with 25 μL electrocompetent&amp;lt;br/&amp;gt;E. coli XL1-Blue MRF’. Electroporation was performed&amp;lt;br/&amp;gt;with 0.1 cm prechilled cuvettes using a&amp;lt;br/&amp;gt;MicroPulser electroporator (BioRad, München) at&amp;lt;br/&amp;gt;1.7 kV. Immediately, 1 mL prewarmed 37°C SOC&amp;lt;br/&amp;gt;medium pH 7.0 (2% (w/v) tryptone, 0.5% (w/v) yeast&amp;lt;br/&amp;gt;extract, 0.05% (w/v) NaCl, 20 mM Mg solution, 20 mM&amp;lt;br/&amp;gt;glucose) was added and incubated for 1 h at 600 rpm&amp;lt;br/&amp;gt;and 37°C. Transformation was plated out on 25 cm&amp;lt;br/&amp;gt;square Petri dishes with 2xYT-GAT agar (1,6% (w/v)&amp;lt;br/&amp;gt;Tryptone, 1% (w/v) yeast extract, 0,5% (w/v) NaCl,&amp;lt;br/&amp;gt;100 mM glucose, 100 μg/mL ampiciline, 20 μg/mL&amp;lt;br/&amp;gt;tetracycline, 1.5% (w/v) agar-agar) and incubated overnight&amp;lt;br/&amp;gt;at 37°C. In parallel 10−6 dilutions of each transformation&amp;lt;br/&amp;gt;reaction were plated out to determine the&amp;lt;br/&amp;gt;transformation rate. These plates were used also for&amp;lt;br/&amp;gt;quality control by colony PCR using the oligonucleotide&amp;lt;br/&amp;gt;primers MHLacZ-Pro_f and MHgIII_r to verify the insert&amp;lt;br/&amp;gt;size. The colonies were scraped from the 25 cm plates&amp;lt;br/&amp;gt;using 40 mL 2xYT medium (1,6% (w/v) Tryptone, 1%&amp;lt;br/&amp;gt;(w/v) yeast extract, 0,5% (w/v) NaCl) and 5 mL were directly&amp;lt;br/&amp;gt;used for midi plasmid preparation using the Nucleobond&amp;lt;br/&amp;gt;Plasmid Midi Kit (Macherey-Nagel).&amp;lt;br/&amp;gt;For VH cloning material from 44 donors of the previous&amp;lt;br/&amp;gt;described HAL7/8 libraries [31] was used in addition&amp;lt;br/&amp;gt;to material of 54 new donors. In a first step 5 μg&amp;lt;br/&amp;gt;pHAL30-VL sublibraries and 2 μg VH PCR products&amp;lt;br/&amp;gt;were digested in a volume of 100 μL using 30 U NcoIHF&amp;lt;br/&amp;gt;and 30 U HindIII-HF (NEB) at 37°C for 3 h. This&amp;lt;br/&amp;gt;step was performed several times to produce enough&amp;lt;br/&amp;gt;material for 150–200 transformations. The digestions,&amp;lt;br/&amp;gt;ligations and transformations were performed as described&amp;lt;br/&amp;gt;for VL cloning with following modifications.&amp;lt;br/&amp;gt;Ligation was performed with 250 ng VH PCR product.&amp;lt;br/&amp;gt;After transformation of XL1-Blue MRF’, overnight incubation&amp;lt;br/&amp;gt;on 25 cm 2 × YT-GAT plates and resuspension in&amp;lt;br/&amp;gt;25 mL 2 × YT medium, glycerol stocks of each library&amp;lt;br/&amp;gt;were made using 800 μL bacteria solution (~1010 bacteria)&amp;lt;br/&amp;gt;and 200 μL glycerol (Roth, Karlsruhe) and stored&amp;lt;br/&amp;gt;at −80°C. For the final library one glycerol stock of each&amp;lt;br/&amp;gt;sublibrary was thawed, mixed together, aliquoted (1 mL)&amp;lt;br/&amp;gt;and stored at −80°C.&amp;lt;br/&amp;gt;The antibody gene libraries HAL9/10 were packaged&amp;lt;br/&amp;gt;separately inoculating 400 mL 2 × YT-GA (2 × YT containing&amp;lt;br/&amp;gt;100 ug/mL ampicillin and 100 mM glucose)&amp;lt;br/&amp;gt;with a library glycerol stock. The bacteria were grown to&amp;lt;br/&amp;gt;an optical density at 600 nm (OD600) of 0.4–0.5 at 37°C&amp;lt;br/&amp;gt;and 250 rpm. 25 mL bacterial culture (~1.25 × 1010 cells)&amp;lt;br/&amp;gt;were infected with 2.5 × 1011 Hyperphage particles [38],&amp;lt;br/&amp;gt;incubated at 37°C for 30 min without shaking followed&amp;lt;br/&amp;gt;by 30 min at 250 rpm. Infected cells were harvested by&amp;lt;br/&amp;gt;centrifugation for 10 min at 3220xg. The pellet was resuspended&amp;lt;br/&amp;gt;in 400 mL 2 × YT-AK (2 × YT containing&amp;lt;br/&amp;gt;100 ug/mL ampicillin and 50 mg/mL kanamycin).&amp;lt;br/&amp;gt;Phage were produced at 30°C and 250 rpm over night.&amp;lt;br/&amp;gt;The bacteria were centrifuged for 20 min at 10,000 × g.&amp;lt;br/&amp;gt;Phage particles in the supernatant were precipitated with&amp;lt;br/&amp;gt;1/5 volume of 20% (w/v) polyethylene glycol (PEG)/&amp;lt;br/&amp;gt;2.5 M NaCl solution for one hour on ice with gentle&amp;lt;br/&amp;gt;shaking and pelleted by centrifugation for one hour at&amp;lt;br/&amp;gt;10,000 × g at 4°C. The precipitated phage were resuspended&amp;lt;br/&amp;gt;in 10 mL phage dilution buffer (10 mM TrisHCl&amp;lt;br/&amp;gt;pH 7.5, 20 mM NaCl, 2 mM EDTA), 1/5 volume of PEG&amp;lt;br/&amp;gt;solution was added and incubated on ice for 20 min,&amp;lt;br/&amp;gt;followed by centrifugation for 30 min at 10,000 × g and&amp;lt;br/&amp;gt;4°C. The pellet was resupended in 1 mL phage dilution&amp;lt;br/&amp;gt;buffer. Residual bacteria and cell debris were removed&amp;lt;br/&amp;gt;by additional centrifugation for 5 min at 16000 × g at&amp;lt;br/&amp;gt;20°C. Supernatants containing antibody phage were&amp;lt;br/&amp;gt;stored at 4°C. Phage titration was done as described before&amp;lt;br/&amp;gt;[41]. The scFv display rates of the packaged libraries&amp;lt;br/&amp;gt;were analyzed by 10% SDS-PAGE, Western blot and&amp;lt;br/&amp;gt;anti-pIII immunostain (mouse anti-pIII 1:2000, goat&amp;lt;br/&amp;gt;anti-mouse IgG AP conjugate 1:10000). Wildtype pIII&amp;lt;br/&amp;gt;has a calculated molecular mass of 42.5 kDa, but it&amp;lt;br/&amp;gt;runs at an apparent molecular mass of 65 kDa in SDSPAGE&amp;lt;br/&amp;gt;[42]. Accordingly, the scFv::pIII fusion protein&amp;lt;br/&amp;gt;runs at about 95 kDa.&lt;br /&gt;
&lt;br /&gt;
Journal of Biotechnology, A human scFv antibody generation pipeline for proteome research, Michael Hust∗,&lt;br /&gt;
[[Category:Antibodies]]&lt;/div&gt;</summary>
		<author><name>Paul.xu</name></author>
	</entry>
</feed>